Reduce or run out

Healthcare professionals urged to conserve tenecteplase (Metalyse) in wake of shortage due to surging global demand, to maintain continuity of supply for patients Boehringer Ingelheim Australia has advised the TGA of shortages of both strengths of their thrombolytic product tenecteplase (Metalyse) injection until the end of next year, with recommendations now put forward on how

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous High-dose PPI changes ‘effective’: PBAC
Next Trials imminent for funded independent prescribers